[12] Patent
[11] Patent No.:GC0009479  
[45] Date of Publishing the Grant of the Patent: 31/Dec /2018                56/2018  
Number of the Decision to Grant the Patent:2018/142496
Date of the Decision to Grant the Patent:30/Dec/2018

[21] Application No.:GC 2010-15445

[22] Filing Date:14/3/2010

[30] Priority:

[33] State [32] Priority date [31] Priority No.
GB
26/11/2009
0920699.6

[72] Inventors:1- Whitlock, Steve،2- Harding, Deborah Phyllis،3- Turner, Carl David

[73] Owner: EURO-CELTIQUE S.A, 2 Avenue Charles Degaulle, Luxembourg, L-1653, Luxembourg

[74] Agent: Saba & Co. T.M.P

  

 

  

[51]IPC:
Int. Cl.: C07D489/12; A61K31/4353; A61P29/00 (2006.01)

[56] Cited Documents:

-EP 1439179 A1 (Z. c/o Inst. of Pharmacology and Toxicology GONG, Y. c/o Inst. of Pharmacology and Toxicology LIU, B. c/o Inst. of Pharmacology and Toxicology QIN, Y. c/o Inst. of Pharmacology and Toxicology WANG, B c/o Inst. of Pharmacology and Toxicology ZHONG) 21 July 2004
-US 5849915 A (Yong Hae Kim, Jin Kyu Park, Kwon Kim, Hee Sock Park) 15 December 1998
 
Examiner: PH. Ahlam S. AlMusallam

[54] DIHYDROETORPHINE
[57] Abstract: The present invention provides a process for the preparation of a compound of formula (VI), or a salt or derivative thereof, wherein R1 and R2 are independently C1-8 alkyl and * represents a stereocentre
No. of claims: 36     No. of figures: 23


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.